As per the terms of the agreement, Endo is expected to retain all rights to the molecules developed, while Syngene will receive research fees, milestone payments and success fees from Endo Pharma.
Kiran Mazumdar-Shaw, CMD at Biocon Group, said: “We are very pleased to enter into this collaboration with Endo Pharmaceuticals as it showcases Syngene’s expertise as an integrated custom research service provider. This agreement is also very significant considering the fact that it is for the first time in India that such a deal has been signed involving the discovery of a biological therapeutic entity.”
Sandeep Gupta, vice president of drug discovery and early development at Endo, said: “We look forward to collaborating with Syngene’s experienced team in our efforts to discover novel treatment for oncology and deliver solutions to patients and providers. This collaboration which marks our entry into biologis discovery space, is consistent with our strategy of building Endo’s pipeline using a visual discovery approach, in conjunction with our in-licensing efforts.”